Abstract

Overexpression of alpha synuclein has been implicated in Parkinson's disease (PD), therefore pharmacological approaches that drive to stimulate the breakdown or degradation of the clusters of alpha synuclein might give a hope in attenuating the progression of the disease.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call